Mary M Horowitz

11PUBLICATIONS
93CO-AUTHORS
Regenerative medicine (incl. stem cells)Gene and molecular therapyTe hauora me te oranga o te Māori kāore anō kia whakarōpūhia i wāhi kē (Māori health and wellbeing not elsewhere classified)Medical mycologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Sep 18, 2025
Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation.

Stephanie J Lee, Brent Logan, Mary M Horowitz

|Jan 03, 2025
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703.

Shernan G Holtan, Javier Bolaños-Meade, Monzr M Al Malki

|Jul 31, 2024
Reply to S. Fuji.

Mark J Levis, Mehdi Hamadani, Mary M Horowitz

|May 03, 2024
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival.

Marcelo C Pasquini, Paul K Wallace, Brent Logan

|Mar 12, 2024
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.

Mark J Levis, Mehdi Hamadani, Brent Logan

|Aug 22, 2023
Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study.

Jurjen Versluis, Wael Saber, Harrison K Tsai

Pageof 2